Brean sees big upside for Endocyte on vintafolide potential

Brean starts Endocyte (ECYT) — which rose 7% Friday — at Buy.

Analyst Gene Mack's $21 target is derived by discounting potential revenue from the Merck-partnered (MRK), folate receptor-targeting cancer treatment vintafolide.

Mack sees peak worldwide sales of $2B in 2026 and notes that potential sales of vintafolide and its companion diagnostic etarfolatide in ovarian cancer alone add $6 to the discounted revenue model.

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs